Skip to main content

Johnson & Johnson Q3 FY2026 results

  • JNJ · NYSE
  • Healthcare
  • Pharmaceuticals
  • S&P 500
$285.75+0.79%Close 13 Nov 2026 · Market value $684.4B

Johnson & Johnson reported revenue of $25.4 billion, up 5.9% from a year earlier, net income of $210 million and diluted earnings per share of $0.09 against $2.12 for the third quarter of fiscal 2026 (the three months to 27 Sep 2026).

From its quarterly report, the results first announced on 13 Oct 2026. Compiled and checked by AapWire.

Q3 FY2026 against Q3 FY2025

Three months to 27 Sep 2026, against the three months to 28 Sep 2025. Amounts in USD.

Johnson & Johnson Q3 FY2026 results against the year-ago quarter
MeasureQ3 FY2026Q3 FY2025Change
Revenue$25.40B$23.99B+5.9%
Gross profit$17.30B$16.69B+3.7%
Gross margin68.1%69.6%−1.4 pts
Operating income$5.84B$7.03B−16.9%
Operating margin23.0%29.3%−6.3 pts
Net income$210.0M$5.15B−95.9%
Diluted EPS$0.09$2.12−95.8%
Operating cash flow$7.72B$9.17B−15.8%
Capital expenditure$1.36B$1.16B+17.7%
Free cash flow$6.36B$8.01B−20.6%

Operating KPIs for the quarter

Johnson & Johnson operating KPIs, Q3 FY2026
KPIQ3 FY2026Change on a year
MedTech worldwide operational sales (change on a year)2.5%down 3.1 points
Oncology revenue$7.6Bup 16.4%
Immunology revenue$4.2Bup 1.3%
Neuroscience revenue$2.4Bup 17.3%
Cardiovascular revenue$2.3Bup 4.2%
Pulmonary Hypertension revenue$897.0Mdown 19.6%
Cardiovascular/Metabolism/Other revenue$849.0Mdown 5.6%
Infectious Diseases revenue$813.0Mdown 1.9%
Shockwave revenue$325.0Mup 16.9%
Innovative Medicine revenue$16.8Bup 7.7%
MEDTECH revenue$8.6Bup 2.5%
United States revenue$15.0Bup 9.1%
Non-US revenue$10.4Bup 1.5%
Europe revenue$5.4Bdown 0.6%
Asia-Pacific, Africa revenue$3.7Bup 1.0%
Western Hemisphere, excluding U.S. revenue$1.4Bup 12.5%

Earlier quarters

Johnson & Johnson results, last eight filed quarters
QuarterPeriod endRevenueChange on a yearDiluted EPS
Q3 FY202627 Sep 2026$25.40B+5.9%$0.09
Q2 FY202628 Jun 2026$25.31B+6.6%$2.27
Q1 FY202629 Mar 2026$24.06B+9.9%$2.14
Q4 FY202528 Dec 2025$24.56B+9.1%$2.09
Q3 FY202528 Sep 2025$23.99B+6.8%$2.12
Q2 FY202529 Jun 2025$23.74B+5.8%$2.29
Q1 FY202530 Mar 2025$21.89B+2.4%$4.54
Q4 FY202429 Dec 2024$22.52B+5.3%$1.41

More on Johnson & Johnson: financial statements · revenue · earnings per share

JNJ's results, as they are filed.

Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.